title: [Prognosis in the cases with renal cell carcinoma according to clinical parameters].
abstract: BACKGROUND
  The objects of this study is to evaluate the clinical prognostic factors in renal cell carcinoma.
  
  
  METHODS
  During a 30-year period from January 1965 to December 1994, 1301 cases with renal cell carcinoma were treated at the Yokohama City University Hospital and its affiliated hospitals. In these cases, cause specific 679 cases from January 1965 to December 1990 were analyzed in a study undertaken to investigate long-term treatment results and clinical prognostic factors.
  
  
  RESULTS
  1. The cause specific 5-, 10-, 15-, and 20-year survival rates were 48.7%, 41.1%, 32.3%, and 26.5% respectively, indicating thus that a great number of cases had an ominous prognosis even 5 years or moreafter surgical treatment. 2. Among patients under 40 years of age (n = 29) none died more than 2 years after receiving operation, the prognosis for this particular group of cases being relatively good. 3. Female, incidentally detected cancer, small tumor size (< or = 4.0 cm), slow growing type and low stage were proven to be favourable prognostic factors in renal cell carcinoma. 4. The cause specific 5-year survival rate for the patients (n = 239) from 1965 to 1981 was 33.8%, while the rate for the patients (n = 440) from 1982 to 1990 was 56.5%. This improvement of survival rate was brought by the increase of the incidentally detected renal cell carcinoma. 5. In the incidentally detected renal cell carcinoma, the incidence of slow growing cases and the cases of less than 4.0 cm tumor size were higher than in the symptomatic renal cell carcinoma. 6. Multivariate analysis using Cox's proportional hazard model showed that stage was the most important prognostic factor.
  
  
  CONCLUSIONS
  These results suggested that sex, age, symptom, tumor size, growing type, and stage were important prognostic factors in renal cell carcinoma.
authors.affiliation: R.C.C. Study Group, Yokohama City University.
authors.forename: M
authors.initials: M
authors.lastname: Fukuda
authors.forename: Y
authors.initials: Y
authors.lastname: Satomi
authors.forename: T
authors.initials: T
authors.lastname: Asakura
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: T
authors.initials: T
authors.lastname: Kishida
authors.forename: I
authors.initials: I
authors.lastname: Kondou
authors.forename: T
authors.initials: T
authors.lastname: Ida
authors.forename: M
authors.initials: M
authors.lastname: Hirokawa
authors.forename: H
authors.initials: H
authors.lastname: Kumagai
authors.forename: H
authors.initials: H
authors.lastname: Shiozaki
authors.forename: E
authors.initials: E
authors.lastname: Ishizuka
authors.forename: K
authors.initials: K
authors.lastname: Miyai
authors.forename: H
authors.initials: H
authors.lastname: Fukuoka
authors.forename: K
authors.initials: K
authors.lastname: Sasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Oogo
authors.forename: T
authors.initials: T
authors.lastname: Koudaira
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: M
authors.initials: M
authors.lastname: Nakahashi
authors.forename: K
authors.initials: K
authors.lastname: Matsuura
authors.forename: M
authors.initials: M
authors.lastname: Moriyama
authors.forename: K
authors.initials: K
authors.lastname: Udagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Senga
authors.forename: Y
authors.initials: Y
authors.lastname: Ishibashi
authors.forename: H
authors.initials: H
authors.lastname: Shimura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate